The estimated Net Worth of Langdon L Miller is at least $105 Thousand dollars as of 22 July 2021. Langdon Miller owns over 10,000 units of Cytocom Inc stock worth over $31,700 and over the last 10 years he sold CBLI stock worth over $0. In addition, he makes $73,725 as President and Chief Medical Officer at Cytocom Inc.
Sign up
Langdon Miller CBLI stock SEC Form 4 insiders trading
Langdon has made over 1 trades of the Cytocom Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of CBLI stock worth $30,000 on 22 July 2021.
The largest trade he's ever made was exercising 10,000 units of Cytocom Inc stock on 22 July 2021 worth over $30,000. On average, Langdon trades about 5,000 units every 0 days since 2015. As of 22 July 2021 he still owns at least 10,000 units of Cytocom Inc stock.
You can see the complete history of Langdon Miller stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Langdon Miller biography
Dr. Langdon L. Miller M.D. serves as President, Chief Medical Officer of the Company. He previously served as a strategic adviser to the Company beginning in 2014. Dr. Miller has maintained a drug development consultancy, Sound Clinical Solutions, SP, located in Seattle, WA since 2013 and has served as a consulting Chief Medical Officer to Oncternal Therapeutics, Inc., located in San Diego, CA, since August 2016. Dr. Miller has served on the board of Dunn Gardens, a private, not-for-profit organization, since 2013 and was appointed to the board of Swedish Club, a private, not-for-profit organization in April of 2019. Since April 2018, Dr. Miller has also served as Executive Vice President and Chief Medical Officer of VelosBio Inc., a private biopharmaceutical company. Dr. Miller has more than 25 years of experience in the design and conduct of translational and clinical drug development programs in oncology (both in hematological and solid tumors) and orphan diseases (including cystic fibrosis, muscular dystrophy, and hemophilia). He has worked in all phases (phase 1-4) of drug development, from first-in-human studies through pivotal registration-directed trials to medical affairs programs and has filed multiple INDs, CTAs, NDAs and orphan drug applications. Dr. Miller played major roles in the development of filgrastim and sargramostim, in the regulatory approvals of irinotecan, exemestane, epirubicin, dexrazoxane, sunitinib, and idelalisib in several cancers, and in validating new endpoints for Duchenne muscular dystrophy and cystic fibrosis. He has extensive experience in the generation, analysis, presentation, and justification of drug development programs before regulatory authorities, advisory committees, investigators, investors, and business development partners. He has authored over 100 regulatory documents and publications. Dr. Miller has held leadership positions in government and in large and small biopharmaceutical companies. He was a Senior Investigator at the National Cancer Institute from 1989 to
What is the salary of Langdon Miller?
As the President and Chief Medical Officer of Cytocom Inc, the total compensation of Langdon Miller at Cytocom Inc is $73,725. There are 1 executives at Cytocom Inc getting paid more, with Christopher Zosh having the highest compensation of $103,494.
How old is Langdon Miller?
Langdon Miller is 66, he's been the President and Chief Medical Officer of Cytocom Inc since 2015. There are no older and 8 younger executives at Cytocom Inc.
What's Langdon Miller's mailing address?
Langdon's mailing address filed with the SEC is C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET, BUFFALO, NY, 14203.
Insiders trading at Cytocom Inc
Over the last 17 years, insiders at Cytocom Inc have traded over $1,157,190 worth of Cytocom Inc stock and bought 66,403 units worth $199,902 . The most active insiders traders include James Antal, Michael Fonstein, and Bernard L Kasten. On average, Cytocom Inc executives and independent directors trade stock every 101 days with the average trade being worth of $21,921. The most recent stock trade was executed by Langdon L Miller on 22 July 2021, trading 10,000 units of CBLI stock currently worth $30,000.
What does Cytocom Inc's logo look like?
Complete history of Langdon Miller stock trades at Cytocom Inc
Cytocom Inc executives and stock owners
Cytocom Inc executives and other stock owners filed with the SEC include:
-
Christopher Zosh,
Interim Principal Executive Officer and Principal Financial Officer, Vice President of Finance -
Langdon Miller,
President, Chief Medical Officer -
Andrei Gudkov,
Chief Scientific Officer -
Lea Verny,
Independent Chairman of the Board -
Daniil Talyanskiy,
Independent Director -
Randy Saluck,
Independent Director -
Anna Evdokimova,
Independent Director -
Alexander Andryushechkin,
Independent Director -
Ivan Fedyunin,
Independent Director -
Anthony Principi,
Director -
C Neil Lyons,
Chief Financial Officer -
Elena Kasimova,
Director -
Yakov Kogan,
EVP of Bus. Development, Sec. -
Richard Mc Gowan,
Director -
James Antal,
Director -
Daniel Floyd Jr Hoth,
Director -
Julia R Brown,
Director -
Alexander Polinsky,
Director -
David C Hohn,
Director -
Bernard L Kasten,
Director -
Jean Viallet,
Chief Development Officer -
Paul E Di Corleto,
Director -
Michael Fonstein,
CEO & President -
Hector Daniel Perez,
Director -
John A Jr Marhofer,
Chief Financial Officer -
Securities Corp Sunrise,
10% owner -
Michael K Handley,
President and CEO -
Robert Buckheit,
Chief Technology Officer -
Cozette M. Mc Avoy,
Chief Legal Officer -
Clifford Selsky,
Chief Medical Officer -
Peter Aronstam,
Chief Financial Officer